Blood nerve barrier permeability enables nerve targeting of circulating nanoparticles in experimental autoimmune...

Guillain-Barré syndrome (GBS) is a devastating autoimmune disease of the peripheral nervous system (PNS) with limited treatment options. Several studies have shown attenuation of the well-characterized GBS preclinical experimental autoimmune neuritis (EAN) model with systemically administered therapeutic compounds via anti-inflammatory or immunomodulatory mechanisms. Despite this, clinical advancement of these findings is limited by dosing that is not translatable to humans or is associated with off-target and toxic effects. This is due, in part, to the blood-nerve barrier (BNB), which restricts access of the circulation to peripheral nerves. However, during acute neuroinflammation, the normally restrictive BNB exhibits increased vascular permeability and enables immune cell infiltration. This may offer a unique window to access the otherwise restricted peripheral nerve microenvironment for therapeutic delivery. Here, we assessed the degree to which BNB permeability and immune cell infiltration over the course of EAN enables accumulation of circulating nanoparticles. We found that at disease stages defined by distinct clinical scores and pathology (onset, effector phase, and peak of EAN severity), intravenously administered small molecules and nanoparticles ranging from 50 to 150 nm can permeate into the endoneurium from the endoneurial vasculature in a size- and stage-dependent manner. This permeation occurs uniformly in both sciatic nerves and in proximal and distal regions of the nerves. We propose that this nerve targeting enabled by pathology serves as a platform by which potential therapies for GBS can be reevaluated and investigated preclinically in nanoparticle delivery systems.